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SUMMARY
Reactivation of the pluripotency network during so-
matic cell reprogramming by exogenous transcription
factors involveschromatin remodelingand the recruit-
ment of RNA polymerase II (Pol II) to target loci. Here,
we report that Pol II is engaged at pluripotency pro-
moters in reprogramming but remains paused and
inefficiently released. We also show that bromodo-
main-containing protein 4 (BRD4) stimulates produc-
tive transcriptional elongation of pluripotency genes
by dissociating the pause release factor P-TEFb
from an inactive complex containing HEXIM1. Conse-
quently, BRD4 overexpression enhances reprogram-
ming efficiency and HEXIM1 suppresses it, whereas
Brd4 and Hexim1 knockdown do the opposite. We
further demonstrate that the reprogramming factor
KLF4 helps recruit P-TEFb to pluripotency promoters.
Our work thus provides a mechanism for explaining
the reactivation of pluripotency genes in reprogram-
ming and unveils an unanticipated role for KLF4 in
transcriptional pause release.
INTRODUCTION
The enforced expression of defined transcription factors can
change cell fate (Sindhu et al., 2012). A striking example of this
phenomenon is the reprogramming of induced pluripotent
stem cells (iPSCs) from somatic cells by the Yamanaka factors
(OCT4, SOX2, KLF4, and c-MYC; OSKM) (Takahashi and Yama-
naka, 2006). Because of their ability to differentiate into diverse
cell lineages, iPSCs provide a potential supply of cells for regen-
erative medicine and also an excellent platform for in vitro dis-
ease modeling and toxicology screening (Saha and Jaenisch,
2009).
Reprogramming is characterized by the existence of road-
blocks that tend to derail the process (Apostolou and Hochedlin-
ger, 2013). Gene expression analyses of bulk populations have
helped clarify these roadblocks and contributed to dividing re-
programming into distinct phases, e.g., initiation, maturation,
and stabilization (Samavarchi-Tehrani et al., 2010). The notion
that gene transcription in reprogramming is phased has also
been validated using single-cell profiling at different time points
(Buganim et al., 2012) and with expression arrays of defined in-
termediate cell populations (Polo et al., 2012). Elucidating the
rate-limiting steps regulating the different phases of gene tran-
scription in reprogramming is important because this may help
improve the methodology.
Gene transcription in metazoans is highly regulated and com-
prises multiple steps (Min et al., 2011). Formation of the preinitia-
tion complex involves the recruitment of several general
transcription factors in addition to Pol II and has traditionally
been considered the major rate-limiting step of gene transcrip-
tion. Consistent with this idea, overexpressing specific subunits
of the general transcription factor TFIID potentiates reprogram-
ming by facilitating pluripotency gene transcription (Pijnappel
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et al., 2013). Pausing of activated Pol II 30–50 nucleotides
downstream of +1 and its release by the P-TEFb complex consti-
tutes another rate-limiting step of gene transcription that has
received growing attention in recent years (Levine, 2011).
Although Pol II pause release was originally thought to represent
a rather specialized mechanism of transcriptional regulation,
analysis of nascent RNAs using global run-on sequencing
(GRO-sequencing) (Min et al., 2011) has shown that around
one-third of genes in the metazoan genome experience this
mode of regulation at some point during the organism’s lifetime
(Levine, 2011). In this regard, genes regulated through pause
release are particularly prevalent in stress responses and during
embryonic development (Smith and Shilatifard, 2013). Poten-
tially, this is becausePol II pausingand its subsequent release en-
ables a method of rapid and synchronous activation of gene
expression programs. Pol II pausing might also be a mechanism
to hold the activation of specialized gene programs during cell
fate conversions if not stimulatedproperly throughpause release.
Here, we demonstrate that the transition of Pol II from a
paused to a productive elongation stage is a rate-limiting step
for inducing pluripotency genes in the late phase of reprogram-
ming. This transition is promoted by the recruitment of active
P-TEFb to pluripotency gene promoters, which is simultaneously
coordinated by BRD4 and KLF4. Our study thus proposes a
revised model for the reactivation of the pluripotency network
in reprogramming.
RESULTS
A Major Change in Transcriptional Regulation
Characterizes the Late Phase of Reprogramming
It has been reported that reprogramming comprises two major
waves of gene transcription (Polo et al., 2012). The first wave in-
volves the upregulation of genes related to proliferation, meta-
bolism, and cytoskeletal organization, while the second wave
is mostly genes related to the pluripotency network. Because
mouse embryonic fibroblasts (MEFs) are very different from
pluripotent cells,weenvisaged that variations in themodeof tran-
scriptional regulation occur during reprogramming. To test this,
we initially contrasted the genes upregulated in the two waves
of reprogramming with a previous GRO-sequencing data set of
MEFs and embryonic stem cells (ESCs) (Min et al., 2011). This
study divided genes into four classes: (1) not paused and tran-
scribed, which show concentration of GRO-sequencing reads
along the gene body (class I, Figure 1A); (2) paused and tran-
scribed, which show concentration of GRO-sequencing reads
in the proximal promoter and less pronouncedly along the gene
body (class II, Figure 1A); (3) paused and not transcribed; and
(4) not paused and not transcribed. Roughly 35%–40% of all
RefSeq genes were shown to belong to class II in both MEFs
and ESCs, but the kind of genes varied in each cell type.
Our comparative analysis showed that genes upregulated in
the first wave of reprogramming mostly belong to class II in
both ESCs and MEFs (606 genes out of 816) (Figure 1B and Fig-
ure S1A available online). Conversely, the second wave is sub-
stantially depleted of class II genes in both MEFs and ESCs
and is enriched in class II genes in ESCs only (Figure 1B and Fig-
ure S1A). Average density of nascent RNA along the promoter
and gene body regions of all class II genes induced in the second
wave of reprogramming confirmed higher levels of Pol II pausing
and pause release in ESCs than in MEFs (Figure S1B). We
conclude that many genes activated in the second wave of re-
programming must experience a change in their mode of tran-
scriptional regulation compared to MEFs. This change consists
in the pausing of Pol II at their proximal promoters and the sub-
sequent pause release to enter productive elongation.
Pol II Is Paused at Pluripotency Promoters during
Reprogramming
We then hypothesized that productive transcriptional elongation
of pluripotency genes could represent a rate-limiting step of re-
programming. To explore this, we performed ChIP-sequencing
for Pol II in MEFs reprogrammed with OSKM at days 5 and 8;
ESCs and untransduced MEFs were used as controls. The Pol
II traveling ratio (TR), which compares the average density of
Pol II in the proximal promoter and gene body (Figure 1C), was
employed to calculate the degree of pausing among different
genes. Consistent with previous reports, we used a TR > 4 as
indicative of Pol II pausing (Zeitlinger et al., 2007). Notably,
approximately half of the genes upregulated in the second
wave of reprogramming displayed a TR > 4 in OSKM reprogram-
ming at day 8 (Figure 1D), but the same genes showed a signifi-
cantly lower value at day 5 and in untransduced MEFs (Figures
1E and 1F). There was good correlation between second wave
genes paused at day 8 of reprogramming and those classified
as class II in ESCs in the GRO-sequencing data analysis (Fig-
ureS1C). In addition, comparisonwithourPol II ChIP-sequencing
data in ESCs showed that a large fraction (55%) of second wave
genes has lower TR in ESCs than at day 8of reprogramming, indi-
cating that they experience productive elongation in ESCs (Fig-
ures 1G–1I). Among those genes there are key pluripotency
regulators including Oct4 and Nanog (Figure 1G). Interestingly,
Oct4 showed substantial pausing at day 5 as well, indicating
that for some pluripotency regulators Pol II is recruited early to
their promoters but remains paused until the late phase (Fig-
ure 1J). Notably, the noncoding pluripotency regulator Mir290
also exhibited Pol II pausing at day 8 of reprogramming (Fig-
ure S1D). The Pol II binding pattern of a class II gene in MEFs,
Thy1, which is downregulated early in reprogramming, is shown
as a control (Figure 1K). Therefore, Pol II pausing at pluripotency
promoters characterizes reprogramming, strongly suggesting
that productive transcriptional elongation is limiting for this
process.
Pause Release Factor P-TEFb Controls the Reactivation
of Pluripotency Genes in Reprogramming
To demonstrate that transcriptional pause release of pluripo-
tency genes is limiting for reprogramming, we focused on
CDK9, the catalytic subunit of the P-TEFb complex, because
it stimulates elongation by phosphorylating Pol II and the
negative elongation factors DSIF and NELF (Zhou and Yik,
2006). We observed increased CDK9 expression (assessed
by western blotting and quantitative PCR [qPCR]) in ESCs
compared to that in MEFs, and we also observed such during
the reprogramming of MEFs with OSKM factors delivered as
retroviruses (Figure 2A and Figures S2A and S2B). To reduce
CDK9 activity, we prepared a retrovirus producing a dominant-
negative form (a kinase inactive mutant) of CDK9 (CDK9-DN)
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Figure 1. Pol II Is Paused at Pluripotency Genes in Reprogramming
(A) GRO-sequencing maps of Rcor1 and Pttg1 in ESCs from the reanalysis of a previous data set (GSE27037).
(B) Venn diagrams show the number of genes upregulated in the first and second wave of reprogramming that belong to class II in MEFs, ESCs, or both.
(C) Schematic representation describing how to calculate the TR.
(D) Percentage of second wave genes that experience Pol II pausing at day 8 of reprogramming. D indicates day.
(E) Pol II TR distribution of second wave genes paused at day 8 of reprogramming compared to day 5 and untransduced MEFs.
(F) Box plots showing the average TR of second wave genes paused at day 8 of reprogramming compared to day 5 and untransduced MEFs.
(G) Percentage of second wave genes paused at day 8 of reprogramming that experience pause release in ESCs.
(legend continued on next page)
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and two independent retroviral shRNA vectors (Figure S2C),
which were transduced along with OSKM into MEFs bearing
an Oct4-GFP transgenic reporter. Reducing CDK9 activity
(tested using CDK9-DN) did not alter exogenous OSKM ex-
pression level and only impaired cell proliferation moderately
(Figures S2D and S2E). Notably, OSKM reprogramming with
CDK9-DN or the two shRNAs allowed the formation of AP+ col-
onies (an early marker of reprogramming) (Buganim et al., 2013),
but these were mostly GFP compared to the controls (Figures
2B–2E), indicating incomplete reprogramming. We achieved the
same result using a different reprogramming system, Oct4-GFP
transgenic MEFs with an integrated OSKM cassette in the
Col1a1 locus, hereafter termed secondary MEFs (Figures S2F
and S2G). We also overexpressed CDK9 during OSKM reprog-
ramming but observed no change in the number of GFP+
colonies (Figure S2H).
To confirm the selective role of CDK9 in the late phase of
reprogramming, we employed a doxycycline-inducible lenti-
virus producing CDK9-DN (Figure S2I) and a known CDK9 in-
hibitor (flavopiridol) (Rahl et al., 2010). Both approaches
impaired the appearance of GFP+ colonies if induced/
administered in the late phase (day 7 to day 11) of reprogram-
ming, but not in the early phase (day 0 to day 5) (Figures 2F
and 2G and Figures S2J and S2K). We also performed
RNA-sequencing of MEFs reprogrammed with OSKM in the
presence or absence of CDK9-DN. Interestingly, CDK9-DN
induced rather modest changes in gene transcription in the
early phase of reprogramming compared to the control (Fig-
ures 2H and 2I). Of note, the well-known CDK9 target Hexim1
was among the downregulated genes (He et al., 2006) (Table
S1). Conversely, CDK9-DN led to the downregulation of a
large number of genes at day 10, many of which belong to
the second transcriptional wave of reprogramming (Figures
2H–2J and Table S1). The selective effect of ablating CDK9
function on the late phase of reprogramming was validated
by qPCR of mesenchymal and epithelial genes in MEFs reprog-
rammed with OSKM and CDK9-DN at day 5 (Figure S2L) and
by qPCR of pluripotency genes at day 9 (Figure 2K). Overall
our data support the idea that high levels of P-TEFb activity
are dispensable in the early phase of reprogramming but instru-
mental for reactivating the pluripotency network in the late
phase.
BRD4 Is a Positive Regulator of Reprogramming
The experiments above showing that CDK9 overexpression
does not enhance the formation of GFP+ colonies led us to
speculate that CDK9 enzymatic activity, but not its overall
expression level, is a limiting factor for reprogramming.
Supporting this possibility, a big proportion of CDK9 is held inac-
tive in a complex containing HEXIM1 in many cell types (Zhou
and Yik, 2006). It is also well known that the bromodomain and
extraterminal (BET) family member BRD4 activates CDK9 by dis-
placing HEXIM1. BRD4 thus appeared as a candidate for further
exploration.
There are two different splice isoforms of BRD4 (short and
long). They share the amino terminal domain (two tandem bro-
modomains [BDs]), responsible for interacting with acetylated
histones, and the extraterminal (ET) domain (Belkina and Denis,
2012). However, only the carboxy terminal domain (CTD) of the
long isoform allows interaction with CDK9 and its activation.
The short isoform of BRD4 displayed low expression level by
qPCR (based on the qPCR cycle threshold [Ct] value) in MEFs
and ESCs (Figure S3A), so we did not study it further. Notably,
qPCR and western blot of the long isoform of BRD4 (hereafter
named BRD4) showed higher expression in ESCs compared to
MEFs and an increase of such during OSKM reprogramming
(Figure 3A and Figures S3A and S3B). We then reduced BRD4
levels in OSKM reprogramming with two independent retroviral
shRNA vectors (Figure S3C). The two shRNAs enabled the for-
mation of AP+ colonies but greatly diminished the appearance
of GFP+ colonies (Figures 3B and 3C), matching the pattern pre-
viously observed for CDK9 inhibition. Moreover, we could not
detect any obvious change in cell proliferation (Figure S3D).
The negative effect on reprogramming efficiency of Brd4 knock-
down was confirmed using secondary MEFs (Figure S3E). In
addition, we observed that the BRD4 inhibitor JQ1 (Belkina
and Denis, 2012) did not affect reprogramming efficiency when
administered in the early phase, but significantly reduced re-
programming efficiency in the late phase (Figures 3D and 3E).
Next, we reprogrammed MEFs with OSKM and a retroviral
vector producing BRD4. This increased the number of GFP+ col-
onies (3-fold) without noticeably changing the appearance of
AP+ colonies (Figures 3F and 3G). Exogenous BRD4 also accel-
erated the formation of GFP+ colonies compared to the control
(Figure 3H) but did not affect cell proliferation (Figure S3F). The
enhancing effect on reprogramming of BRD4 overexpression
was confirmed using secondary MEFs (Figure S3G). Moreover,
iPSC colonies generated with BRD4 and OSKM contained the
Brd4 retrovirus in their genome and were fully pluripotent (Fig-
ure 3I and Figures S3H–S3K). These data indicate that BRD4 is
a positive regulator of the late phase of reprogramming.
BRD4 Potentiates Reprogramming through P-TEFb
Because BRD4 has CDK9-independent functions (Belkina and
Denis, 2012), we tested whether it regulates reprogramming
specifically through the activation of CDK9. We prepared retro-
viral vectors producing a series of truncations that correspond
to the major functional domains of BRD4 (Figure 4A). Only those
BRD4 constructs retaining the CTD, including BRD4-CTD, were
able to pull down endogenous CDK9 when overexpressed in
HEK293T cells (Figure 4B). We overexpressed these different
truncations together with OSKM in MEFs. Interestingly, BRD4-
BD acted as a dominant-negative for endogenous BRD4,
reducing GFP+ colonies (Figure 4C) but without obviously
changing the number of AP+ colonies (Figure S4A). This effect
is likely related to the ability of this construct to diminish the inter-
action of endogenous BRD4 with chromatin. As predicted,
BRD4-D-CTD also failed to enhance, and even reduced, the
(H) Pol II TR distribution of second wave genes paused at day 8 of reprogramming that are released in ESCs.
(I) Box plots showing the average TR of second wave genes paused at day 8 of reprogramming that are released in ESCs.
(J and K) Pol II occupancy on Oct4 and Thy1 in MEFs, in ESCs, and at two different time points during reprogramming.
See also Figure S1.
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Figure 2. P-TEFb Regulates the Activation of Pluripotency Genes in the Late Phase of Reprogramming
(A) Western blot for endogenous CDK9 in MEFs and ESCs (left) or during reprogramming (right). Histone H3 (H3) was used as loading control.
(B) Phase contrast (left), fluorescence photographs (middle), and AP-stained wells (right) of MEFs reprogrammed with OSKM and CDK9-DN at day 10. An empty
vector was used as a control (Ctrl; also hereafter in similar experiments). Scale bar represents 50 mm.
(C) Number of GFP+ colonies at day 12 in MEFs reprogrammed as in (B). Average colony numbers of three independent experiments are shown.
(D) Phase contrast (left), fluorescence photographs (middle), and AP-stained wells (right) of MEFs reprogrammed with OSKM and two independent shRNAs for
Cdk9 (shCdk9) at day 10. shRNA against firefly luciferase was used as a control (shCtrl; also hereafter in similar experiments). Scale bar represents 50 mm.
(E) Number of GFP+ colonies at day 12 in MEFs reprogrammed as in (D). Average colony numbers of three independent experiments are shown.
(F and G) Number of GFP+ colonies at day 11 in MEFs reprogrammed with OSKM and an inducible CDK9-DN (teton CDK9-DN). Doxycycline (dox; 2 mg/ml) was
administered daily for the indicated time periods. The dotted lines are used to highlight deviations from the mean number of colonies in untreated control wells
(also hereafter in selected experiments). Average colony numbers of two independent experiments are shown.
(H) Heatmap of RNA-sequencing data showing the expression level of genes corresponding to the first (for days 3, 4, and 5) and second (for day 10) wave of
reprogramming in MEFs reprogrammed with OSKM and empty vector or CDK9-DN.
(I) Number of RefSeq genes significantly differentially regulated (fold change >1.25, false discovery rate or FDR < 0.01) by CDK9-DN in the early phase (in all three
time points) and late phase of OSKM reprogramming.
(legend continued on next page)
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number of GFP+ colonies compared to the control (Figure 4C). In
addition, we observed that BRD4-CTD reproducibly enhanced
the formation of GFP+ colonies 3-fold over intact BRD4 (Fig-
ure 4C). This suggested that the ET domain of BRD4 might
contain a module that impairs reprogramming, perhaps through
interaction with negative regulators. Supporting this idea, a trun-
cated form of BRD4 (BRD4-D-ET) that only lacks the ET domain
(Figure 4A) increased the number of GFP+ colonies to a level
closer to that of BRD4-CTD (Figure 4C). One possible candidate
mediating this negative effect is CHD4, which belongs to the
MBD3/NuRD complex with repressive function in reprogram-
ming (Rais et al., 2013), because it is known to interact with
BRD4 through the ET domain (Rahman et al., 2011). We also de-
tected that overexpressing BRD4-ET inhibited rather than
enhanced the number of GFP+ colonies (Figure 4C). This implies
that overexpressed BRD4-ET might interact as well with positive
regulators of reprogramming, thus titrating down their interaction
with endogenous BRD4.
To further show that the effect of BRD4-CTD is mediated
through CDK9, we prepared two mutant forms (CTD-FEE/AAA
and CTD-R/P) that cannot interact with CDK9 (Figure 4D).
Consistent with previous studies (Bisgrove et al., 2007),
these mutants could not pull down endogenous CDK9 in immu-
noprecipitation assays (Figure 4E) and failed to increase the for-
mation of GFP+ colonies over the baseline in MEFs reprog-
rammed with OSKM (Figure 4F). Introducing the same
mutations into full-length BRD4 (BRD4-FEE/AAA and BRD4-R/
P) had the same outcome (Figure 4G). We also validated the
effect of all BRD4 constructs in secondary MEFs (Figures S4B
and S4C). Likewise, we employed a polycistronic OSKM
lentiviral vector and BRD4-CTD to reprogram a noninvasive re-
programmable human cell source, urinary cells (Zhou et al.,
2012). BRD4-CTD significantly increased the number of human
ESC-like colonies using cells from three independent donors
(Figure 4H). We picked eight independent colonies from one
donor; they could be expanded retaining ESC-like morphology
(Figure 4I), had integrated the BRD4-CTD transgene, and were
fully pluripotent (Figure 4I and Figures S4D–S4F). Collectively,
these experiments demonstrate that BRD4 enhances reprog-
ramming (mouse and human) through CDK9.
BRD4 Stimulates Productive Elongation at Pluripotency
Genes in Reprogramming and ESCs
To demonstrate that BRD4 facilitates the activation of the plurip-
otency network in the late phase of reprogramming, we per-
formed qPCR of MEFs reprogrammed with OSKM and
BRD4-CTD at day 9. As expected, BRD4-CTD induced a sub-
stantial increase in the expression of pluripotency genes
belonging to the second transcriptional wave of reprogramming
(Figure 5A), but there was no significant change in epithelial or
mesenchymal genes at day 5 (Figure 5B). Next, we studied
whether the effect of BRD4 on pluripotency genes is due to
stimulation of transcriptional elongation. For this purpose, we
selected eight candidates induced in the secondwave of reprog-
ramming: Nanog, Oct4, Sall4, Sox2, Dppa2, Rex1, Esrrb, and
Utf1. ChIP-qPCR along the promoter and coding region of these
genes showed that BRD4-CTD increases Pol II binding to the
gene body compared to the control, indicating more productive
elongation (Figure 5C and Figure S5A). Similar results were
observed performing ChIP for Pol II phosphorylated on serine
2 (Ser2P), a posttranslational modification triggered by CDK9
that specifically identifies elongating Pol II (Zhou and Yik, 2006)
(Figure 5C and Figure S5A).
If our hypothesis that BRD4 is amajor regulator of pluripotency
genes during reprogramming were true, one might also expect
that reducing BRD4 expression should blunt pluripotency genes
in ESCs. However, a previous genome-wide siRNA screening in
ESCs showed cell death but not differentiation uponBrd4 knock-
down (Fazzio et al., 2008). To clarify this issue, we reduced Brd4
expression in ESCs with two independent lentiviral shRNA vec-
tors (Figure S5B). This caused quick (within 4 days) acquisition
of a differentiated morphology and concomitant loss of AP stain-
ing and OCT4-GFP signal, which was associated with reduced
expression of pluripotency genes and enhanced expression of
lineage-specific genes (Figures 5D and 5E and Figure S5C). In
addition, we overexpressed BRD4-CTD in ESCs before letting
them differentiate by withdrawing LIF. BRD4-CTD had a moder-
ate effect in both sustaining pluripotency genes and preventing
the increase of lineage-specific genes, but it could not prevent
the quick (within 4 days) loss of ESCmorphology and AP staining
(Figures S5D and S5E). Finally, to further demonstrate that BRD4
regulates pluripotency genes, we analyzed a BRD4 ChIP-
sequencing data set from ESCs. This showed strong binding of
BRD4 at the promoter regions of multiple pluripotency genes
including Nanog and Oct4 (Figure 5F). Hence, BRD4 regulates
pluripotency gene expression in reprogramming and in ESCs.
Differences between our work and the study by Fazzio et al.
(2008) may rely on the extent of Brd4 knockdown, which is likely
stronger with the siRNA, and may point to an additional function
of BRD4 in regulating the ESC cell cycle.
Inhibition of P-TEFb Activity by HEXIM1 Impairs the
Reactivation of Pluripotency Genes in Reprogramming
Because the reprogramming booster BRD4 enhances P-TEFb
activity by displacing HEXIM1 bound to CDK9 (Zhou and Yik,
2006), we postulated that HEXIM1 is a roadblock to reprogram-
ming. To evaluate this, we reprogrammed MEFs with OSKM and
a retroviral vector producing HEXIM1. As expected, this reduced
the interaction between endogenous BRD4 and CDK9, as as-
sessed by immunoprecipitation of CDK9 at day 9 of reprogram-
ming (Figure 6A). HEXIM1 overexpression also reduced cell
proliferation (Figure S6A), in agreement with previous work in
other contexts (Hong et al., 2012). Nevertheless, a significant
number of AP+ colonies still formed, though these were mostly
(J) Percentage of RefSeq and second wave genes upregulated and downregulated (fold change >1.25, FDR < 0.01) or unchanged by CDK9-DN at day 10 of
reprogramming.
(K) qPCR for the indicated genes using RNA lysates fromMEFs reprogrammed with OSKM and empty vector or CDK9-DN at day 9. Endo- indicates endogenous.
Values are referred to untransduced MEFs.
The data in (C), (E), (F), (G), and (K) are reported as mean values ± standard deviation (SD) with the indicated significance (*p < 0.05, **p < 0.01, ***p < 0.005). See
also Figure S2 and Table S1.
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GFP (Figures 6B and 6C). A similar effect was observed with
HEXIM1 overexpression in secondary MEFs (Figure S6B).
We then tested the effect on OSKM reprogramming of two in-
dependent retroviral shRNA vectors for Hexim1. These shRNAs
knocked down Hexim1 efficiently and substantially enhanced
the interaction between endogenous BRD4 and CDK9 (Fig-
ure 6D). They also increased the formation of GFP+ colony for-
mation by 3- to 4-fold, which was not associated with an
obvious change in the number of AP+ colonies (Figures 6E and
6F). Similar results were obtained knocking downHexim1 in sec-
ondary MEFs (Figure S6C). Moreover, we reprogrammed MEFs
with OSKM and Hexim1 shRNA in optimized culture conditions
(Chen et al., 2010). This achieved over 71%GFP+ cells assessed
by FACS (Figures 6G and 6H). We confirmed that the iPSCs
produced by knocking down Hexim1 had integrated the shRNA
vectors into their genome and were fully pluripotent (Figures
S6D–S6H). We also employed qPCR of MEFs reprogrammed
with OSKM in standard medium at day 9 to show that HEXIM1
overexpression prevents the activation of pluripotency genes
while its knockdown enhances it (Figures 6I and 6J). In addition,
we studied whether Hexim1 knocking down with a lentiviral
shRNA vector maintains pluripotency gene expression in ESCs
deprived of LIF by sustaining CDK9 activation through BRD4.
There was only a mild change in pluripotency or lineage-specific
genes in ESCs transduced with Hexim1 shRNA (Figure S6I).
Therefore, HEXIM1 constitutes a barrier for the reactivation of
pluripotency genes in the late phase of reprogramming but
does not seem to control the dismantling of the pluripotency
network in the early stages of ESC differentiation.
KLF4 Recruits CDK9 to Pluripotency Gene Promoters in
Reprogramming and ESCs
Transcription factors help recruit CDK9 to specific loci (Romano
and Giordano, 2008). We thus predicted that the reprogramming
factors support CDK9 binding at pluripotency genes in the late
phase of reprogramming and in ESCs. In this regard, c-MYC is
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Figure 3. BRD4 Enhances Reprogramming
(A) Western blot for endogenous BRD4 in MEFs and ESCs (top) or during reprogramming (bottom). Histone H3 (H3) was used as the loading control.
(B) Phase contrast (left), fluorescence photographs (middle), and AP-stained wells (right) of MEFs reprogrammed with OSKM and shRNA control or two shRNAs
for Brd4 (shBrd4) at day 10. Scale bar represents 50 mm.
(C) Number of GFP+ colonies at day 12 in MEFs reprogrammed as in (B). Average colony numbers of three independent experiments are shown.
(D and E) Number of GFP+ colonies in MEFs reprogrammed with OSKM and the BRD4 inhibitor JQ1 (100 nM). DMSO was used as a control. Colonies were
counted at day 13 (D) or day 11 (E). Average colony numbers of two independent experiments are shown.
(F) Number of GFP+ colonies at day 11 in MEFs reprogrammed with OSKM and empty vector or BRD4. Average colony numbers of three independent
experiments are shown.
(G) AP-stained wells of a representative experiment as in (F) at day 10.
(H) Schematic representation of the time of GFP+ colony appearance during OSKM reprogramming with or without exogenous BRD4.
(I) Immunofluorescence, phase contrast photographs, and chimeric mice with germline transmission (red arrow) obtained with a representative iPSC colony
produced with OSKM and BRD4. Scale bar represents 50 mm.
The data in (C)–(F) are reported as mean values ± SD with the indicated significance (*p < 0.05, **p < 0.01, ***p < 0.005).
See also Figure S3.
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known to recruit CDK9 to a subset of gene promoters (mostly
related to cell cycle and metabolism) in ESCs (Rahl et al.,
2010). Yet, exogenous c-MYC did not seem a good candidate
because it is necessary at the beginning of reprogramming but
dispensable afterward (Polo et al., 2012; Sridharan et al.,
2009). To confirm this, we reprogrammedMEFswith retroviruses
producing the three other Yamanaka factors (OSK) together with
BRD4, BRD4-CTD, or Hexim1 shRNA. All three approaches
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(A) Schematic depiction of wild-type BRD4 and the different truncated BRD4 mutants used in this study.
(B) Immunoprecipitation (IP) of the different BRD4 variants (FLAG-tagged) shown in (A) in HEK293T cells. FLAG-tagged GFP was used as control. Membranes
were immunoblotted (IB) for CDK9 and FLAG. Black arrows indicate specific bands.
(C) Number of GFP+ colonies at day 11 in MEFs reprogrammed with OSKM and empty vector or the indicated BRD4 variants. Average colony numbers of three
independent experiments are shown.
(D) Schematic depiction of the location of the CDK9 binding site on BRD4 and the corresponding modifications performed to abolish their interaction.
(E) Immunoprecipitation of the indicated BRD4 variants (FLAG-tagged) in HEK293T cells. FLAG-tagged GFP was used as a control. Membranes were
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(I) Phase contrast and immunofluorescence photographs of human iPSCs produced from urinary cells transduced with OSKM and BRD4-CTD. Scale bar
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The data in (C) and (F)–(H) are reported as mean values ± SD with the indicated significance (*p < 0.05, **p < 0.01, ***p < 0.005).
See also Figure S4.
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significantly enhanced the number of GFP+ colonies (Figures 7A
and 7B). Then, we analyzed the role of endogenous c-MYC in
OSK reprogramming using a c-MYC inhibitor (10058-F4) (Rahl
et al., 2010), which blunted GFP+ colony formation if added in
the early or late phase of reprogramming (Figure S7A). This
effect was associated with reduced proliferation and increased
apoptosis (Figures S7B and S7C), differing significantly from
the mode of action shown above for CDK9 and BRD4 inhibition.
We also analyzed the binding of c-MYC on genes belonging to
the second wave of reprogramming using a ChIP-sequencing
data set from ESCs (Chen et al., 2008). This showed that fewer
than 20% of the genes in the second wave are bound by
c-MYC in ESCs, among which core pluripotency factors such
asNanog andOct4 are not included (Figure S7D). Although these
results don’t formally exclude the possibility that endogenous
c-MYC participates in CDK9 recruitment to pluripotency loci,
they strongly suggest that other mechanisms coexist.
To study whether CDK9 interacts with any of the other three
reprogramming factors, we transfected OCT4, SOX2, KLF4,
and c-MYC (as a positive control) individually in HEK293T cells.
Exogenous c-MYC and KLF4, but not OCT4 and SOX2, could
pull down endogenous CDK9 in immunoprecipitation assays
(Figure 7C and Figure S7E). We verified the interaction between
KLF4 and endogenous CDK9 in MEFs reprogrammed with
OSKM at day 9 (Figure 7D). In addition, we compared previous
ChIP-sequencing data sets for CDK9 and 13 ESC transcription
factors (among them OCT4, SOX2, KLF4, and c-MYC) or chro-
matin regulators (Chen et al., 2008; Whyte et al., 2013). CDK9
binding genome-wide showed prominent correlation with KLF4
binding (and also ESRRB and TFCP2L1) but weaker correlation
with the core pluripotency module containing OCT4 and SOX2
(in green) or the MYC module containing c-MYC and n-MYC (in
blue) (Figure 7E). Accordingly, the top 1,000 KLF4-bound genes
in ESCs had significantly higher CDK9 ChIP-sequencing signals
than the bottom 1,000 (Figure S7F), and the same was observed
when the reverse comparison was performed (Figure S7G). Like-
wise, we analyzed the average enrichment of CDK9, KLF4, and
c-MYC around promoter regions genome-wide in ESCs, which
showed higher levels of co-occupancy by CDK9/KLF4 than
CDK9/c-MYC (Figure 7F). We also observed that 70% of the
genes upregulated in the second wave of reprogramming are
KLF4 targets in ESCs (Figure S7H) and CDK9 also binds to
many of them (Figure S7I). Consequently, differences in the pro-
moter enrichment between CDK9/KLF4 and CDK9/c-MYC
became more obvious when only second wave genes were
used for the analysis (Figure 7G), which is illustrated by CDK9
and KLF4 binding (but not c-MYC) atNanog andOct4 promoters
(Figure 7H and Figure S7J). We further confirmed that KLF4 and
CDK9 bind together at pluripotency genes using sequential ChIP
(first for KLF4 and then for CDK9) in ESCs, MEFs, and two time
points during reprogramming (Figures 7I and 7J and Figure S7K).
To demonstrate that CDK9 binding and pause release at plurip-
otency genes is KLF4 dependent, we also transduced ESCswith
an effective lentiviral shRNA vector forKlf4 (Figure S7L). In agree-
ment with a previous report (Zhang et al., 2010), Klf4 knockdown
caused quick reduction of pluripotency gene expression (within
4 days) (Figure S7M). This was associated with reduced loading
of CDK9 onto the corresponding promoters (Figure 7K) and of
Pol II (total and Ser2P) on the gene body as early as 48 hr after
transduction (Figure 7L). Therefore, KLF4 helps stabilize CDK9
binding at pluripotency gene promoters, contributing to promote
Pol II pause release at pluripotency loci.
DISCUSSION
We have demonstrated that Pol II pause release mediated by
P-TEFb is a rate-limiting step for the reactivation of pluripotency
genes in reprogramming. This process is mediated by the coor-
dinated effects of KLF4 and BRD4 (Figure 7M). We employed
bulk populations rather than specific reprogramming intermedi-
ates. Yet, the rather high levels of Pol II enrichment and pausing
at many pluripotency genes suggest that this may be a general
phenomenon occurring as well in cell populations refractory
to reprogramming. In this regard, it is worth noting that
induction of pause release in standard medium only enhances
reprogramming in a proportion of cells, indicating the need to
simultaneously remove other roadblocks to achieve high reprog-
ramming efficiency.
Our model showing that KLF4 has a more dominant effect
than c-MYC in recruiting P-TEFb to pluripotency promoters in
the late phase of reprogramming and in ESCs is compatible
with the proposed activating role of KLF4 in the second tran-
scriptional wave of reprogramming (Polo et al., 2012). It also cor-
relates with the observation that treating ESCs with flavopiridol
reduces the expression of many genes controlled by pause
release that are not bound by c-MYC (Rahl et al., 2010). More-
over, a recent report proposed that in oncogenic transformation
c-MYC mostly controls Pol II recruitment but not pause release
(Sabo` et al., 2014), suggesting that a similar phenomenon partic-
ipates in reprogramming. From a pluripotency perspective, the
new role of KLF4 in controlling pause release may help explain
why ESC function is so well synchronized (Min et al., 2011).
From a somatic cell perspective, it may provide clues into how
KLF4 orchestrates gene activation in normal epithelial homeo-
stasis and disease (e.g., in cancer) (Rowland and Peeper,
2006). Notably, reprogramming can be achieved with cocktails
Figure 5. BRD4 Regulates Transcriptional Pause Release at Pluripotency Genes
(A and B) qPCR for the indicated genes using RNA lysates from MEFs reprogrammed with OSKM and empty vector or BRD4-CTD at day 9 (A) and day 5 (B).
Values are referred to untransduced MEFs.
(C) Upper: schematic representation of the Nanog, Oct4, Sall4, and Sox2 loci. The amplified regions are shown below. Lower: ChIP-qPCR of Pol II (total and
Ser2P) binding at these loci in MEFs reprogrammed with OSKM and empty vector or BRD4-CTD.
(D) AP staining of ESCs transduced with shRNA control or two shRNAs for Brd4. Scale bar represents 50 mm.
(E) qPCR for the indicated pluripotency genes using lysates from ESCs transduced with shRNA control or two shRNAs for Brd4.
(F) BRD4 occupancy on Nanog and Oct4 from the reanalysis of a previous data set (GSE36561).
The data in (A)–(C) and (E) are reported as mean values ± SD with the indicated significance (*p < 0.05, **p < 0.01, ***p < 0.005).
See also Figure S5.
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of exogenous factors that don’t include KLF4 (Buganim et al.,
2012). In these cases, it is possible that one or more of these
alternative transcription factors participate in pluripotency
gene pause release. Likewise, it should be considered that in-
duction of endogenous KLF4 in the late phase of reprogramming
could substitute for exogenous KLF4.
Understanding further how Pol II pausing and pause release at
pluripotency promoters are regulated, and specifically how they
relate to newly acquired chromatin modifications (Apostolou and
Hochedlinger, 2013; Buganim et al., 2013; Koche et al., 2011),
may provide new ways to improve reprogramming. In this re-
gard, it would be interesting to study whether Pol II pausing at
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Figure 6. HEXIM1 Reduces P-TEFb Activity and Blocks Reprogramming
(A) Immunoprecipitation of CDK9 using lysates fromMEFs reprogrammedwith OSKMand empty vector or HEXIM1 at day 9.Membraneswere immunoblotted for
HEXIM1, BRD4, and CDK9.
(B) Phase contrast (left), fluorescence photographs (middle), and AP-stained wells (right) of MEFs reprogrammed with OSKM and HEXIM1 at day 10. Scale bar
represents 50 mm.
(C) Number of GFP+ colonies at day 13 in MEFs reprogrammed as in (B). Average colony numbers of three independent experiments are shown.
(D) Immunoprecipitation of CDK9 using lysates from MEFs reprogrammed with OSKM and shRNA control or two shRNAs for Hexim1 (shHex) at day 9. Mem-
branes were immunoblotted for HEXIM1, BRD4, and CDK9.
(E) AP-stained wells of MEFs reprogrammed with OSKM and shRNA control or two shRNAs for Hexim1 at day 10.
(F) Number of GFP+ colonies at day 11 in MEFs reprogrammed as in (E). Average colony numbers of two independent experiments are shown.
(G) Phase contrast (left) and fluorescence photographs (right) of MEFs reprogrammed with OSKM and shRNA control or shRNA for Hexim1 in iSF1 medium
at day 14. Scale bar represents 50 mm.
(H) OCT4-GFP+ cells analyzed by FACS in MEFs reprogrammed as in (G) at day 14.
(I and J) qPCR for the indicated genes using RNA lysates fromMEFs reprogrammed with OSKM and empty vector or HEXIM1 (I) and shRNA control or shRNA for
Hexim1 (J) at day 9. Values are referred to untransduced MEFs.
The data in (C), (F), (I), and (J) are reported as mean values ± SD with the indicated significance (*p < 0.05, **p < 0.01, ***p < 0.005).
See also Figure S6.
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pluripotency promoters is caused by the coexistence of bivalent
marks (Apostolou and Hochedlinger, 2013), i.e., acquisition of
active H3K4me3 without complete removal of inhibitory
H3K27me3 during the course of reprogramming. In addition,
the role of BRD4, an acetylated histone reader and component
of super-enhancers (Love´n et al., 2013; Whyte et al., 2013), in
promoting reprogramming is also particularly attractive. Among
other possibilities, it is possible that while exogenous transcrip-
tion factors form super-enhancers at distal regions of pluripo-
tency genes, they also induce the acetylation of nearby histones
in order to first recruit BRD4 and then promote pause release
through P-TEFb. This process may also be modulated by the
interaction of BRD4 and the reprogramming factors with other
regulators such as the MBD3/NuRD complex (Rais et al., 2013).
In summary, ourwork provides amechanism that explains how
the pluripotency network is activated in reprogramming and how
it is sustained in ESCs. It is tempting to speculate that stimulating
pause release through BRD4 also improves other types of tran-
scription-factor-based cell fate conversions (Sindhu et al., 2012).
EXPERIMENTAL PROCEDURES
Cell Culture and iPSC Generation
OG2MEFs (Esteban et al., 2010) and OG2 secondary MEFs (Carey et al., 2010)
were obtained from E13.5 embryos carrying the Oct4-GFP transgene by
following standard procedure. Secondary MEFs were derived from mice
carrying an inducible OSKM cassette inserted into the Col1a1 locus that
had been crossed with OG2 mice. MEFs were maintained in DMEM/high
glucose (Hyclone) containing 10% fetal bovine serum (FBS, PAA), GlutaMax
(Invitrogen), nonessential amino acids (Invitrogen), and penicillin/streptomycin
(Hyclone). HEK293T cells and Plat-E cells were maintained in DMEM/high
glucose (Hyclone) containing 10% FBS (PAA). Mouse ESCs and iPSCs were
cultured in mouse ESC medium (DMEM with 15% FBS [GIBCO], GlutaMax,
nonessential amino acids, sodium pyruvate, b-mercaptoethanol, and
1,000 U/ml LIF [Millipore]) on mitomycin-C-treated MEFs or 0.1% gelatin.
Human urinary cells were isolated and cultured as previously described
(Zhou et al., 2012). Mouse and human iPSCs were generated as previously
described (Zhou et al., 2012; Zhuang et al., 2013). Further details are provided
in Supplemental Experimental Procedures.
Plasmids
Full-length Cdk9 was amplified by PCR from cDNAs obtained from MEFs and
was cloned into pMXs vector. Cdk9-DN mutant (Fujinaga et al., 1998) was
generated using QuikChange site-directed mutagenesis kit (Agilent Technolo-
gies). Full-length Brd4 was amplified by PCR from Flag-HA-Brd4 cDNA pur-
chased from Addgene (#14441). The 4.3 kb PCR product was cloned into the
pMXs vector. Truncated deletion mutants were generated by performing
PCR with different primers and were cloned into pMXs. Brd4-FEE/AAA, Brd4-
R/P, Brd4-CTD-FEE/AAA, and Brd4-CTD-R/P mutants were generated using
QuikChange site-directed mutagenesis kit. Flag-HA-tagged Brd4 mutants for
coimmunoprecipitation studies were also purchased from Addgene: Brd4
(#22304), Brd4-D-ET (#21938), Brd4-D-CTD (#31352), Brd4-ET (#31353),
Brd4-CTD (#31354), and Brd4-BD (#32886). Full-length Hexim1 was amplified
by PCR from cDNA obtained from MEFs and cloned into pMXs. The lentiviral
Brd4-CTDwas constructed by subcloning pMXs-Brd4-CTD into pRlenti-based
vector. Cdk9 shRNA inserts were cloned into pRetroSuper. Brd4 and Hexim1
shRNA inserts were cloned into both pRetroSuper vector and pLKO.1 vector.
Klf4 shRNA inserts were cloned into pLKO.1 vector. shRNA target sequences
are listed in Table S2. All plasmids were validated by sequencing.
qPCR, Immunofluorescence, Western Blotting,
Coimmunoprecipitation, ChIP, and Apoptosis Detection
qPCR was performed using SYBR Green (Takara) on an ABI 7500 machine.
Assays were run in triplicate and values were normalized on the basis of
Actb values. Immunofluorescence microscopy was performed using a Leica
TCS SP2 Spectral confocal microscope. Western blotting was performed
using ECL or ECL plus (Amersham). Coimmunoprecipitation and ChIP were
done using protein A/G Dynabeads (Life Technologies). Apoptosis was de-
tected using Annexin V: PE Apoptosis Detection Kit (BD Biosciences). Primary
antibodies and primers are listed in Tables S3 and S4. Further details are pro-
vided in Supplemental Experimental Procedures.
RNA-Sequencing, ChIP-Sequencing, and Bioinformatics Analysis
RNA-sequencing was performed by RiboBio Co., Ltd. ChIP-sequencing was
performed as described with small variations. Further experimental details
and explanations about the bioinformatics analysis are provided in Table S5
and Supplemental Experimental Procedures.
Statistical Analysis
The Student’s t test was used throughout the manuscript.
ACCESSION NUMBERS
RNA-sequencing and ChIP-sequencing data are available in the Gene Expres-
sion Omnibus (GEO) database under the accession number GSE59833.
SUPPLEMENTAL INFORMATION
Supplemental Information for this article includes seven figures, five tables,
and Supplemental Experimental Procedures and can be found with this article
online at http://dx.doi.org/10.1016/j.stem.2014.09.018.
Figure 7. KLF4 Interacts with CDK9 and Shares Overlapping Targets throughout the Genome
(A and B) Number of GFP+ colonies at day 12 in MEFs reprogrammed with OSK and the indicated vectors. Average colony numbers of three (A) or two (B)
independent experiments are shown.
(C) Immunoprecipitation of the indicated proteins (FLAG-tagged) in HEK293T cells. FLAG-tagged GFP was used as control. Membranes were immunoblotted for
CDK9 and FLAG.
(D) Coimmunoprecipitation of endogenous CDK9 with KLF4 in MEFs reprogrammed with OSKM at day 10. Antibodies against IgG were used as a control.
(E) Hierarchical clustering of the indicated transcription factors and chromatin regulators from the reanalysis of previous data sets (GSE11431 and GSE44286).
Colors in the heatmap indicate the correlation between the ChIP-sequencing data sets.
(F and G) Distribution of CDK9, KLF4, and c-MYCChIP-sequencing tags relative to the transcription start site (TSS) of RefSeq genes (F) or second wave genes (G)
obtained from the reanalysis of previous data sets (GSE11431 and GSE44286).
(H) CDK9, KLF4, and c-MYC occupancy on Nanog obtained from the reanalysis of previous data sets (GSE11431 and GSE44286).
(I and J) Sequential ChIP of KLF4 and then CDK9 at the indicated gene promoters in ESCs (I) andMEFs reprogrammed with OSKM at two different time points (J).
Untransduced MEFs were used as a control in (J).
(K) ChIP-qPCR for CDK9 on the Nanog and Oct4 promoters 48 hr after ESCs were transduced with shRNA control or shRNA for Klf4 (shKlf4).
(L) Upper: schematic representation of theNanog andOct4 loci and the regions amplified in the ChIP-qPCR. Lower: ChIP-qPCR of Pol II (total and Ser2P) binding
to these loci 48 hr after transducing ESCs with shRNA control or shRNA for Klf4.
(M) Schematic representation of the main message of our work.
The data in (A), (B), and (I)–(L) are reported as mean values ± SD with the indicated significance (*p < 0.05, **p < 0.01, ***p < 0.005).
See also Figure S7.
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